BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22485110)

  • 1. Ebolavirus Replication and Tetherin/BST-2.
    Yasuda J
    Front Microbiol; 2012; 3():111. PubMed ID: 22485110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells.
    Hoffmann M; Nehlmeier I; Brinkmann C; Krähling V; Behner L; Moldenhauer AS; Krüger N; Nehls J; Schindler M; Hoenen T; Maisner A; Becker S; Pöhlmann S
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.
    González-Hernández M; Hoffmann M; Brinkmann C; Nehls J; Winkler M; Schindler M; Pöhlmann S
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.
    Kühl A; Banning C; Marzi A; Votteler J; Steffen I; Bertram S; Glowacka I; Konrad A; Stürzl M; Guo JT; Schubert U; Feldmann H; Behrens G; Schindler M; Pöhlmann S
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S850-60. PubMed ID: 21987761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperation of the Ebola Virus Proteins VP40 and GP
    Rizk MG; Basler CF; Guatelli J
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 7. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
    J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein disulfide isomerases (PDIs) negatively regulate ebolavirus structural glycoprotein expression in the endoplasmic reticulum (ER) via the autophagy-lysosomal pathway.
    Wang B; Zhang J; Liu X; Chai Q; Lu X; Yao X; Yang Z; Sun L; Johnson SF; Schwartz RC; Zheng YH
    Autophagy; 2022 Oct; 18(10):2350-2367. PubMed ID: 35130104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40.
    Yu DS; Weng TH; Shen L; Wu XX; Hu CY; Wang FXC; Wu ZG; Wu HB; Wu NP; Li LJ; Yao H
    Cell Physiol Biochem; 2018; 50(3):1055-1067. PubMed ID: 30355918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.
    Gustin JK; Bai Y; Moses AV; Douglas JL
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S181-90. PubMed ID: 25821226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
    Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
    J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin B & L are not required for ebola virus replication.
    Marzi A; Reinheckel T; Feldmann H
    PLoS Negl Trop Dis; 2012; 6(12):e1923. PubMed ID: 23236527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin.
    Radoshitzky SR; Dong L; Chi X; Clester JC; Retterer C; Spurgers K; Kuhn JH; Sandwick S; Ruthel G; Kota K; Boltz D; Warren T; Kranzusch PJ; Whelan SP; Bavari S
    J Virol; 2010 Oct; 84(20):10569-80. PubMed ID: 20686043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitin Ligase WWP1 Interacts with Ebola Virus VP40 To Regulate Egress.
    Han Z; Sagum CA; Takizawa F; Ruthel G; Berry CT; Kong J; Sunyer JO; Freedman BD; Bedford MT; Sidhu SS; Sudol M; Harty RN
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.
    Lopez LA; Yang SJ; Exline CM; Rengarajan S; Haworth KG; Cannon PM
    J Virol; 2012 May; 86(10):5467-80. PubMed ID: 22398279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.
    Kaletsky RL; Francica JR; Agrawal-Gamse C; Bates P
    Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2886-91. PubMed ID: 19179289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.
    Williams CG; Gibbons JS; Keiffer TR; Luthra P; Edwards MR; Basler CF
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus.
    Ayouba A; Touré A; Butel C; Keita AK; Binetruy F; Sow MS; Foulongne V; Delaporte E; Peeters M
    J Clin Microbiol; 2017 Jan; 55(1):165-176. PubMed ID: 27795350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
    Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.